AC
Armistice Capital Portfolio holdings
AUM
$2.64B
1-Year Return
0.99%
This Quarter Return
+1.45%
1 Year Return
+0.99%
3 Year Return
+16.29%
5 Year Return
+18.04%
10 Year Return
+34.8%
AUM
$4.3B
AUM Growth
+$476M
(+12%)
Cap. Flow
+$486M
Cap. Flow
% of AUM
11.31%
Top 10 Holdings %
Top 10 Hldgs %
29.76%
Holding
319
New
63
Increased
77
Reduced
60
Closed
90
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$97M |
| 2 |
Exact Sciences
EXAS
|
$90.9M |
| 3 |
Icon
ICLR
|
$87.7M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$71.6M |
| 5 |
GSK
GSK
|
$62.7M |
Top Sells
| 1 |
Alkermes
ALKS
|
$40.5M |
| 2 |
PTC Therapeutics
PTCT
|
$38.7M |
| 3 |
Shake Shack
SHAK
|
$34.8M |
| 4 |
Incyte
INCY
|
$29.6M |
| 5 |
Cytokinetics
CYTK
|
$27.5M |
Sector Composition
| 1 | Healthcare | 67.09% |
| 2 | Consumer Discretionary | 10.89% |
| 3 | Consumer Staples | 9.15% |
| 4 | Technology | 8.92% |
| 5 | Communication Services | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Intensity Therapeutics
INTS
$12.9M
| $1.98M | 0.03% |
+1,126,868
| New | +$1.98M |
|
|
DPRO
152
Draganfly
DPRO
$82.3M
| $1.93M | 0.03% |
+480,794
| New | +$1.93M |
|
153
Arqit Quantum
ARQQ
$414M
| $1.83M | 0.02% |
+47,000
| New | +$1.83M |
|
154
Momentus
MNTS
$14M
| $1.72M | 0.02% |
+217,259
| New | +$1.72M |
|
155
4D Molecular Therapeutics
FDMT
$330M
| $1.67M | 0.02% |
300,000
-36,000
| -11% | -$201K |
|
156
BioXcel Therapeutics
BTAI
$56.6M
| $1.61M | 0.02% |
+269,688
| New | +$1.61M |
|
|
MTVA
157
MetaVia Inc. Common Stock
MTVA
$16.6M
| $1.48M | 0.02% |
728,637
-119,363
| -14% | -$242K |
|
158
Maris-Tech Ltd. Warrants
MTEKW
$2.39M
| $1.26M | 0.02% |
1,261,058
| – | – |
|
159
Signet Jewelers
SIG
$3.85B
| $1.2M | 0.02% |
+14,808
| New | +$1.2M |
|
|
AISP
160
Airship AI Holdings
AISP
$138M
| $1.12M | 0.02% |
178,822
-1,121,178
| -86% | -$7.02M |
|
161
Surrozen
SRZN
$105M
| $1.09M | 0.01% |
75,694
-63,306
| -46% | -$908K |
|
162
Ekso Bionics
EKSO
$10.6M
| $1.05M | 0.01% |
115,043
-29,424
| -20% | -$269K |
|
163
Lexaria Bioscience
LEXX
$20.3M
| $966K | 0.01% |
+460,000
| New | +$966K |
|
164
Mainz Biomed
MYNZ
$7.51M
| $959K | 0.01% |
+222,000
| New | +$959K |
|
165
Nektar Therapeutics
NKTR
$719M
| $952K | 0.01% |
68,267
+1,600
| +2% | +$22.3K |
|
166
HCW Biologics
HCWB
$9.34M
| $903K | 0.01% |
+50,592
| New | +$903K |
|
167
LM Funding America
LMFA
$16.4M
| $791K | 0.01% |
368,000
+91,000
| +33% | +$196K |
|
|
VIVS
168
VivoSim Labs, Inc. Common Stock
VIVS
$6.03M
| $754K | 0.01% |
136,554
+35,054
| +35% | +$193K |
|
169
Mustang Bio
MBIO
$10.4M
| $638K | 0.01% |
+72,131
| New | +$638K |
|
170
Gold Royalty Corp. Warrants, each exercisable for one common share at an exercise price of $2.25 per share
GROY.WS
$297M
| $561K | 0.01% |
2,200,000
| – | – |
|
171
Professional Diversity Network
IPDN
$19.8M
| $559K | 0.01% |
+111,896
| New | +$559K |
|
172
Evogene
EVGN
$10.8M
| $558K | 0.01% |
298,281
+103,589
| +53% | +$194K |
|
173
Moleculin Biotech
MBRX
$11.1M
| $540K | 0.01% |
317,586
+27,586
| +10% | +$46.9K |
|
174
Cosmos Holdings
COSM
$19.8M
| $501K | 0.01% |
748,826
-910,024
| -55% | -$609K |
|
|
AWH
175
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $501K | 0.01% |
710,000
-546,000
| -43% | -$385K |
|